216. Morelli A, Ricci Z, Bellomo R, et al. Prophylactic fenoldopam for renal
protection in sepsis: a randomized, double-blind, placebo-controlled pilot
trial. Crit Care Med 2005; 33: 2451–2456.
217. Aravindan N, Natarajan M, Shaw AD. Fenoldopam inhibits nuclear
translocation of nuclear factor kappa B in a rat model of surgical ischemic
acute renal failure. J Cardiothorac Vasc Anesth 2006; 20: 179–186.
218. Aravindan N, Samuels J, Riedel B, et al. Fenoldopam improves cortico-
medullary oxygen delivery and attenuates angiogenesis gene expression in
acute ischemic renal injury. Kidney Blood Press Res 2006; 29: 165–174.
219. Kellum JA. Prophylactic fenoldopam for renal protection? No, thank you,
not for me–not yet at least. Crit Care Med 2005; 33: 2681–2683.
220. Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the
prevention of contrast-induced nephropathy: a randomized controlled trial.
JAMA 2003; 290: 2284–2291.
221. Tumlin JA, Finkel KW, Murray PT, et al. Fenoldopam mesylate in early
acute tubular necrosis: a randomized, double-blind, placebo-controlled
clinical trial. Am J Kidney Dis 2005; 46: 26–34.
222. Brienza N, Malcangi V, Dalfino L, et al. A comparison between fenoldopam
and low-dose dopamine in early renal dysfunction of critically ill patients.
Crit Care Med 2006; 34: 707–714.
223. Landoni G, Biondi-Zoccai GG, Tumlin JA, et al. Beneficial impact of
fenoldopam in critically ill patients with or at risk for acute renal failure:
a meta-analysis of randomized clinical trials. Am J Kidney Dis 2007; 49:
56–68.
224. Ricksten SE, Sward K. Atrial natriuretic peptide in acute renal failure.
In: Ronco C, Bellomo R, Kellum J (eds). Critical Care Nephrology, 2nd Edn.
Saunders Elsevier: Philadelphia, PA, 2009, pp 429–433.
225. Vesely DL. Natriuretic peptides and acute renal failure. Am J Physiol Renal
Physiol 2003; 285: F167–177.
226. Marin-Grez M, Fleming JT, Steinhausen M. Atrial natriuretic peptide causes
pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat
kidney. Nature 1986; 324: 473–476.
227. Valsson F, Ricksten SE, Hedner T, et al. Effects of atrial natriuretic peptide
on renal function after cardiac surgery and in cyclosporine-treated heart
transplant recipients. J Cardiothorac Vasc Anesth 1994; 8: 425–430.
228. Ratcliffe PJ, Richardson AJ, Kirby JE, et al. Effect of intravenous infusion of
atriopeptin 3 on immediate renal allograft function. Kidney Int 1991; 39:
164–168.
229. Sands JM, Neylan JF, Olson RA, et al. Atrial natriuretic factor does not
improve the outcome of cadaveric renal transplantation. J Am Soc Nephrol
1991; 1: 1081–
1086.
230. Kurnik BR, Allgren RL, Genter FC, et al. Prospective study of atrial
natriuretic peptide for the prevention of radiocontrast-induced nephro-
pathy. Am J Kidney Dis 1998; 31: 674–680.
231. Allgren RL, Marbury TC, Rahman SN, et al. Anaritide in acute tubular
necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N Engl J
Med 1997; 336: 828–834.
232. Lewis J, Salem MM, Chertow GM, et al. Atrial natriuretic factor in oliguric
acute renal failure. Anaritide Acute Renal Failure Study Group. Am J Kidney
Dis 2000; 36: 767–774.
233. Sward K, Valsson F, Odencrants P, et al. Recombinant human atrial
natriuretic peptide in ischemic acute renal failure: a randomized placebo-
controlled trial. Crit Care Med 2004; 32: 1310–1315.
234. Sward K, Valsson F, Sellgren J, et al. Differential effects of human atrial
natriuretic peptide and furosemide on glomerular filtration rate and renal
oxygen consumption in humans. Intensive Care Med 2005; 31: 79–85.
235. Nigwekar SU, Navaneethan SD, Parikh CR, et al. Atrial natriuretic peptide
for management of acute kidney injury: a systematic review and meta-
analysis. Clin J Am Soc Nephrol 2009; 4: 261–272.
236. Forssmann W, Meyer M, Forssmann K. The renal urodilatin system: clinical
implications. Cardiovasc Res 2001; 51: 450–462.
237. Hummel M, Kuhn M, Bub A, et al. Urodilatin: a new peptide with
beneficial effects in the postoperative therapy of cardiac transplant
recipients. Clin Investig 1992; 70: 674–682.
238. Brenner P, Meyer M, Reichenspurner H, et al. Significance of prophylactic
urodilatin (INN: ularitide) infusion for the prevention of acute renal failure
in patients after heart transplantation. Eur J Med Res 1995; 1: 137–143.
239. Sackner-Bernstein JD, Kowalski M, Fox M, et al. Short-term risk of death
after treatment with nesiritide for decompensated heart failure: a pooled
analysis of randomized controlled trials. JAMA 2005; 293: 1900–1905.
240. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal
function with nesiritide in patients with acutely decompensated heart
failure. Circulation 2005; 111: 1487–1491.
241. Topol EJ. Nesiritide - not verified. N Engl J Med 2005; 353: 113–116.
242. Iglesias JI, DePalma L, Hom D, et al. P
redictors of mortality in adult
patients with congestive heart failure receiving nesiritide–retrospective
analysis showing a potential adverse interaction between nesiritide and
acute renal dysfunction. Nephrol Dial Transplant 2008; 23: 144–153.
243. Mentzer RM, Jr., Oz MC, Sladen RN, et al. Effects of perioperative nesiritide
in patients with left ventricular dysfunction undergoing cardiac surgery:the
NAPA Trial. J Am Coll Cardiol 2007; 49: 716–726.
244. Ejaz AA, Martin TD, Johnson RJ, et al. Prophylactic nesiritide does not
prevent dialysis or all-cause mortality in patients undergoing high-risk
cardiac surgery. J Thorac Cardiovasc Surg 2009; 138: 959–964.
245. Lingegowda V, Van QC, Shimada M, et al. Long-term outcome of
patients treated with prophylactic nesiritide for the prevention of acute
kidney injury following cardiovascular surgery. Clin Cardiol 2010; 33:
217–221.
246. Hammerman MR. Potential role of growth factors in the prophylaxis and
treatment of acute renal failure. Kidney Int Suppl 1998; 64: S19–22.
247. Bernhardt WM, Eckardt KU. Physiological basis for the use of
erythropoietin in critically ill patients at risk for acute kidney injury.
Curr Opin Crit Care 2008; 14: 621–626.
248. Ding H, Kopple JD, Cohen A, et al. Recombinant human insulin-like
growth factor-I accelerates recovery and reduces catabolism in rats with
ischemic acute renal failure. J Clin Invest 1993; 91: 2281–2287.
249. Friedlaender M, Popovtzer MM, Weiss O, et al. Insulin-like growth factor-1
(IGF-1) enhances recovery from HgCl2-induced acute renal failure: the
effects on renal IGF-1, IGF-1 receptor, and IGF-binding protein-1 mRNA.
J Am Soc Nephrol 1995; 5: 1782–1791.
250. Miller SB, Martin DR, Kissane J, et al. Insulin-like growth factor I
accelerates recovery from ischemic acute tubular necrosis in the rat.
Proc Natl Acad Sci U S A 1992; 89: 11876–11880.
251. Petrinec D, Reilly JM, Sicard GA, et al. Insulin-like growth factor-I
attenuates delayed graft function in a canine renal autotransplantation
model. Surgery 1996; 120: 221–225; discussion 225–226.
252. Franklin SC, Moulton M, Sicard GA, et al. Insulin-like growth factor I
preserves renal function postoperatively. Am J Physiol 1997; 272: F257–259.
253. Hirschberg R, Kopple J, Lipsett P, et al. Multicenter clinical trial of
recombinant human insulin-like growth factor I in patients with acute renal
failure. Kidney Int 1999; 55: 2423–2432.
254. Hladunewich MA, Corrigan G, Derby GC, et al. A randomized, placebo-
controlled trial of IGF-1 for delayed graft function: a human model to study
postischemic ARF. Kidney Int 2003;
64: 593–
602.
255. Song YR, Lee T, You SJ, et al. Prevention of acute kidney injury by
erythropoietin in patients undergoing coronary artery bypass grafting:
a pilot study. Am J Nephrol 2009; 30: 253–260.
256. Endre ZH, Walker RJ, Pickering JW, et al. Early intervention with
erythropoietin does not affect the outcome of acute kidney injury
(the EARLYARF trial). Kidney Int 2010; 77: 1020–1030.
257. Karlowicz MG, Adelman RD. Nonoliguric and oliguric acute renal failure in
asphyxiated term neonates. Pediatr Nephrol 1995; 9: 718–722.
258. Gouyon JB, Guignard JP. Theophylline prevents the hypoxemia-induced
renal hemodynamic changes in rabbits. Kidney Int 1988; 33: 1078–1083.
259. Bakr AF. Prophylactic theophylline to prevent renal dysfunction in
newborns exposed to perinatal asphyxia–a study in a developing country.
Pediatr Nephrol 2005; 20: 1249–1252.
260. Bhat MA, Shah ZA, Makhdoomi MS, et al. Theophylline for renal function
in term neonates with perinatal asphyxia: a randomized, placebo-controlled
trial. J Pediatr 2006; 149: 180–184.
261. Jenik AG, Ceriani Cernadas JM, Gorenstein A, et al. A randomized, double-
blind, placebo-controlled trial of the effects of prophylactic theophylline on
renal function in term neonates with perinatal asphyxia. Pediatrics 2000;
105: E45.
262. Cattarelli D, Spandrio M, Gasparoni A, et al. A randomised, double blind,
placebo controlled trial of the effect of theophylline in prevention of
vasomotor nephropathy in very preterm neonates with respiratory distress
syndrome. Arch Dis Child Fetal Neonatal Ed 2006; 91: F80–84.
263. Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1
adenosine receptor antagonist, protects against the decline in renal function
observed with diuretic therapy. Circulation 2002; 105: 1348–1353.
264. Givertz MM, Massie BM, Fields TK, et al. The effects of KW-3902, an
adenosine A1-receptor antagonist,on diuresis and renal function in patients
with acute decompensated heart failure and renal impairment or diuretic
resistance. J Am Coll Cardiol 2007; 50: 1551–1560.
265. Cotter G, Dittrich HC, Weatherley BD, et al. The PROTECT pilot study:
a randomized, placebo-controlled, dose-finding study of the adenosine A1
receptor antagonist rolofylline in patients with acute heart failure and renal
impairment. J Card Fail 2008; 14: 631–640.
266. Massie BM, O’Connor CM, Metra M, et al. Rolofylline, an adenosine
A1-receptor antagonist, in acute heart failure. NEnglJMed2010; 363:
1419–1428.
128 Kidney International Supplements (2012) 2, 124–138
references